- Home
- CLPS vs COEP Comparison
CLPS vs COEP Comparison
Compare CLPS & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPS | COEP |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | 7 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 72.7M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLPS | COEP |
|---|---|---|
| Price | $1.02 | $11.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.9K | ★ 32.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 12.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $6.32 |
| 52 Week High | $1.88 | $21.41 |
Technical Indicators
Market Signals| Indicator | CLPS | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 45.45 |
| Support Level | $0.90 | $11.76 |
| Resistance Level | $1.11 | $13.23 |
| Average True Range (ATR) | 0.06 | 0.86 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 47.96 | 35.43 |
Price Performance
Historical ComparisonAbout CLPS CLPS Incorporation
CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.